This article was originally published in The Gray Sheet
Board authorizes a $2 bil. increase in the company's common stock repurchase program, raising the previously approved spending limit of $6 bil. to $8 bil., effective immediately. Since 1994, BMS has repurchased approximately 79 mil. shares of its stock at an aggregate cost of $4 bil
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.